Xu Bin, Scognamiglio Theresa, Cohen Perry R, Prasad Manju L, Hasanovic Adnan, Tuttle Robert Michael, Katabi Nora, Ghossein Ronald A
Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, M4N 3M5.
Department of Pathology, Cornell University, New York, NY, USA, 10065.
Hum Pathol. 2017 Jul;65:133-139. doi: 10.1016/j.humpath.2017.05.013. Epub 2017 May 25.
Metastatic papillary thyroid carcinoma (PTC) without an identifiable primary tumor despite extensive microscopic examination of the thyroid gland is a rare but true phenomenon.We retrieved 7 of such cases and described in detail the clinical and pathologic features of these tumors. BRAF V600E immunohistochemistry and Sequenom molecular profile were conducted in selected cases. All patients harbored metastatic disease in the central (n=3), lateral (n=3), or both neck compartments (n=1). The histotype of the metastatic disease was PTC (n=5), poorly differentiated thyroid carcinoma in association with a PTC columnar variant (n=1), and anaplastic thyroid carcinoma in association with a PTC tall cell variant (n=1). Fibrosis was present in the thyroid of 5 patients. All patients with PTC were alive without evidence of recurrence. The 76-year-old patient with poorly differentiated thyroid carcinoma did not recur and died of unknown causes. Finally, the patient with anaplastic thyroid carcinoma was alive with distant metastasis at last follow-up. The median follow-up for this cohort was 2.2years (range, 0.8-17). BRAF V600E was detected in 4 of 6 cases by immunohistochemistry. In conclusion, metastatic nodal disease without identifiable thyroid primary is a rare but real phenomenon of unknown mechanisms. Although most tumors are low grade and well differentiated, aggressive behavior due to poorly differentiated or anaplastic carcinoma can happen. Most cases are BRAF-positive thyroid tumors. A papillary carcinoma phenotype is found in all reported cases.
转移性甲状腺乳头状癌(PTC),即便对甲状腺进行了广泛的显微镜检查仍未发现可识别的原发肿瘤,这是一种罕见但确实存在的现象。我们检索到7例此类病例,并详细描述了这些肿瘤的临床和病理特征。对部分病例进行了BRAF V600E免疫组化和Sequenom分子分析。所有患者均在中央区(n = 3)、侧区(n = 3)或双侧颈部区域(n = 1)出现转移性疾病。转移灶的组织学类型为PTC(n = 5)、伴PTC柱状变体的低分化甲状腺癌(n = 1)以及伴PTC高细胞变体的未分化甲状腺癌(n = 1)。5例患者的甲状腺存在纤维化。所有PTC患者均存活,无复发迹象。那位患有低分化甲状腺癌的76岁患者未复发,死于不明原因。最后,那位患有未分化甲状腺癌的患者在最后一次随访时仍存活,但有远处转移。该队列的中位随访时间为2.2年(范围0.8 - 17年)。免疫组化在6例中的4例检测到BRAF V600E。总之,无法识别甲状腺原发灶的转移性淋巴结疾病是一种罕见但真实存在的现象,其机制不明。尽管大多数肿瘤为低级别且分化良好,但低分化或未分化癌可能导致侵袭性行为。大多数病例为BRAF阳性的甲状腺肿瘤。所有报道病例均呈现乳头状癌表型。